TCGFB, a private biotech founded by healthcare VC The Column Group, is tapping California biotech Surrozen to discover ...

The funds will be used to advance Agomab’s candidates through clinical trials, including AGMB-129 for patients with ...

as well as the relationship between the extent of traction bronchiectasis and exacerbations in idiopathic pulmonary fibrosis (IPF). The overarching message from the symposium was that advances are ...

Current studies indicate that IL-17B is associated with the occurrence and progression of pulmonary fibrosis and systemic sclerosis. Notably, in systemic sclerosis, there is no statistically ...

Methotrexate (MTX) is the widely agreed upon first-choice second-line agent to treat juvenile idiopathic arthritis ... as has been reported in rheumatoid arthritis. However, preliminary evidence ...

Tyenne ® is indicated for the treatment of several inflammatory and immune diseases, including rheumatoid arthritis (RA), giant cell arteritis (GCA), polyarticular juvenile idiopathic arthritis (pJIA) ...

[5–7] Fashioning after adults with RA, the earliest identified therapies for juvenile rheumatoid arthritis ... second-line agent to treat juvenile idiopathic arthritis (JIA), up to 75% of ...

Liver fibrosis is scarring of the liver. It has many causes, including alcohol-induced damage, infections, and diseases that harm the liver. Inflammation and injury of the liver can lead to scarring, ...

Idiopathic pulmonary fibrosis (an update ... Huang S, Doyle TJ, Hammer MM, et al. Rheumatoid arthritis-related lung disease detected on clinical chest computed tomography imaging: prevalence ...

Idiopathic pulmonary fibrosis (IPF) is characterized by a progressive decline in lung function, worsening quality of life, and high mortality. However, the rate and pattern of progression of IPF ...